Maxwell Biosciences

Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwell's first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides. Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” anti-infectives drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.